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deposits but also chelated soluble Gd. We suggest that the 
analysis should be done after the majority of this soluble 
chelated Gd is most likely excreted. Pietsch et al. demon-
strated that a steady-state level of skin Gd was reached only 
after 53 days p.i. of high doses of linear GBCAs. The time 
to reach steady state depended on the stability level of the 
linear GBCA [1]. Consequently, we think that 53 days p.i. 
would be the earliest reasonable time point for determina-
tion of Gd tissues deposits.
The excretion kinetics of Gd-EOB-DTPA of the animal 
model was not thoroughly described prior to start of the 
experiments. The authors induced hepatic impairment by 
application of carbon tetrachloride (CCl4) without know-
ing the effect of CCl4 on the 1/6 remnant kidney tissue. 
A reasonable first step should have been to describe Gd-
EOB-DTPA kinetics in renally vs hepatorenally impaired 
animals. If this induction of renal and hepatic impairment 
results in extremely prolonged excretion kinetics, GBCA 
would be still circulating 7 day p.i. and would compro-
mise the conclusions on Gd tissue deposits.
In addition, the hepatocyte-specific uptake and hepato-
biliary excretion of Gd-EOB-DTPA are based on the satu-
rable uptake by anion-transporting polypeptide 1 trans-
porters (Oatp1) [2]. Liver fibrosis strongly influences the 
hepatocyte-specific uptake of Gd-EOB-DTPA [3]. There-
fore, evaluation of the pharmacokinetics is a pre-requisite 
to validate this animal model.
Finally, some clinical considerations. Gd-EOB-DTPA 
was administered 12 times over a period of 6 weeks at a 
dose of 0.625 mmol/kg. The approved dose of Gd-EOB-
DTPA is 0.025 mmol/kg for one single liver MRI, which is 
usually sufficient for diagnosis. Thus, this 300 times over-
dosing does not reflect any clinically relevant situation. In 
the rare case that patients have both severe renal and severe 
liver impairments, even more caution would be exercised.
To the editor,
We read with great interest the study by Tomohiro Sato 
et al. published online, January 9, 2015. The authors dem-
onstrated, in an experiment on 2 × 5 rats, that application 
of 0.625 mmol/kg Gd-EOB-DTPA resulted in signifi-
cantly higher gadolinium tissue deposition in hepatorenally 
impaired rats compared to renally impaired rats. The effect 
was statistically significant in kidneys, spleen and liver but 
not in other organs.
Based on the methodology used to detect the tissue gad-
olinium (Gd), the time point of the analysis and the missing 
validation of the animal model, we think that this experi-
mental setting does not allow any conclusions on gadolin-
ium tissue deposits.
The authors state that “ICP-MS cannot distinguish 
between chelated and unchelated Gd”. Thus, the time point 
to analyze Gd tissue deposition is crucial. The authors do 
not provide a rationale for analyzing tissue 7 days after last 
GBCA application. At this early time point, it is reason-
able to assume that the measurements not only assessed Gd 
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In conclusion, based on the methodology used to detect 
the tissue Gd, the time point of the analysis and the missing 
validation of the animal model, we think that this experi-
mental setting does not allow any conclusions on gadolin-
ium tissue deposits. The authors only support the broadly 
accepted hypothesis that reduced elimination kinetics leads 
to a higher gadolinium exposure.
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